DOYLESTOWN, Pa., Jan. 18 /PRNewswire-FirstCall/ -- The Quigley Corporation announced today that Dr. Richard Rosenbloom, COO of Quigley Pharma, will be presenting the research results of the December 1, 2005 Mask Studies using Quigley Pharma's QR-441 compound at the upcoming conference, Bird Flu: The First Pandemic of the 21st Century. A Central Role for Antivirals. The conference is organized by Retroscreen Virology, will be held at the University of London in London, UK, commencing tomorrow, January 19th and ending on the 20th.
Quigley Pharma's QR-441 compound was sprayed on respiratory mask air filters and tested against avian influenza virus (H5N1) and human influenza virus (H3N2). The QR-441 impregnated masks prevented up to 99% of the viruses whereas the masks not treated with QR-441 had the ability to prevent up to 90% of the viruses passing through.
Dr. Rosenbloom's presentation will also offer insight into the more important and significant findings that show that the QR-441 compound was shown to be a virucidal barrier to avian influenza virus (H5N1) and human influenza virus (H3N2) and may be of potential use in the prevention of Influenza transmission and spread.
The study took place at Retroscreen Virology, Queen Mary's School of Medicine and Dentistry, University of London, in the UK, one of the most innovative virological research and clinical trials companies in its field. Studies were conducted under the direction of Dr. Rob Lambkin and Professor John Oxford, Retroscreen Virology's Scientific Director and Professor of Virology at St Bartholomew's and the Royal London Hospital, Queen Mary's School of Medicine and Dentistry.
Dr. Richard Rosenbloom stated: "We are excited at the opportunity to present our mask study findings and discuss the relevance of a compound capable of significantly reducing transmission of the avian influenza virus in controlled laboratory studies within the context of a potential outbreak."
The Quigley Corporation is the leading developer and marketer of diversified health products. The company's proven success in launching first-in-category health solutions supports the Pharma subsidiary in its efforts to develop strong pharmaceutical compounds targeting diverse conditions such as diabetes and rheumatoid arthritis with naturally derived compounds and botanicals.
The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND for human study or take any other action to allow the aforementioned compound to be marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has four (4) wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
CONTACT: Media Investor Relations Karen Pineman Carl Hymans G.S. Schwartz & Co. G.S. Schwartz & Co. 212.725.4500 212.725.4500 kpineman@schwartz.comcarlh@schwartz.com
The Quigley CorporationCONTACT: Media: Karen Pineman, +1-212-725-4500, kpineman@schwartz.com; orInvestors: Carl Hymans, +1-212-725-4500, carlh@schwartz.com, both of G.S.Schwartz & Co., both for The Quigley Corporation
